“We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases” states Carolyn Cross
Vancouver, British Columbia (PRWEB) May 12, 2011
Ondine Biomedical Inc.( TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection based products, is proud to announce that its CEO, Carolyn Cross, has been formally inducted onto the Board of the International Photodynamic Association. The International Photodynamic Association (IPA) was founded in 1986 and its exclusive membership includes the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy. In this position, Ms. Cross will assist the IPA in raising awareness about the benefits of using light and photosensitizers to combat bacterial, viral and fungal infections. The official announcement coincided with the IPA International Congress, May 10-14, 2011 in Innsbruck, Austria.
Photodynamic therapy, a branch of medicine that relies on light to activate molecules and destroy harmful cells, has made a very large impact on the medical community and is now found in numerous areas of medicine including; dentistry, oncology, ophthalmology, infection control and dermatology. Ondine Biomedical Inc. is the global leader in photodisinfection and has recently joined with the Vancouver General Hospital in a combined project to prevent hospital acquired infections, particularly methicilin resistant Staphylococcus aureus (MRSA) surgical site infections. Ondine also continues to develop and collaborate on treatment and prevention systems for various indications, including Ventilator Associated Pneumonia (VAP), Mother-to-Child-Transmission of HIV, cancer, and Chronic Sinusitis.
“We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases,” stated Cross. “Today, we have entered an era where many bacteria have developed resistance to most antibiotics, rendering many of these drugs almost useless. It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine.”
Carolyn Cross has been part of the Ondine Biomedical Inc. board since it was established in 1999. Due to a rapid research and development program, Ondine Biomedical Inc. is now seen as some of the world’s most renowned groups of experts on photodynamic therapy and photodisinfection. It is the hope of Ms. Cross, and the rest of the International Photodynamic Association, that her induction will assist in bringing photodynamic therapy to the forefront of medicine in the future.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to the development of non-antibioticanti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. We are focused on the development and commercialization of our patented light activated technology, photodisinfection. Ondine currently has numerous applications of its photodisinfection technology at various stages of development. Ondine’s lead product is the MRSAid™ nasal decolonization system which is used to decolonize the nares of methicillin-resistant Staphylococcus aureus (MRSA). Other medical applications and next generation products in the hospital acquired infection market are currently under development.
About the International Photodynamic Association
The International Photodynamic Association was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy and photodiagnosis. The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitizers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organizes an International Congress every two years which is a unique way to sum up research activities in the clinical and basic research of PDT.